InsiderTrades.com logo

MNPR Insider Trading

Insider Ownership Percentage: 20.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $37,866,916.69

Monopar Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Monopar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Monopar Therapeutics Share Price & Price History

Current Price: $79.47
Price Change: ▲ Price Increase of +2.29 (2.97%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for MNPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Monopar Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/24/2025Tactic Pharma LlcMajor ShareholderSell550,229$63.61$35,000,066.69272,026View SEC Filing Icon  
7/14/2025Chandler RobinsonCEOSell16,800$40.00$672,000.0073,472View SEC Filing Icon  
7/14/2025Christopher M StarrDirectorSell16,800$40.00$672,000.005,173View SEC Filing Icon  
7/14/2025Kim R TsuchimotoDirectorSell8,904$40.00$356,160.0011,486View SEC Filing Icon  
4/2/2025Tactic Pharma LlcMajor ShareholderSell33,334$35.00$1,166,690.00822,255View SEC Filing Icon  
10/28/2024Karthik RadhakrishnanCFOBuy1,550$16.25$25,187.501,550View SEC Filing Icon  
6/20/2024Andrew CittadineCOOBuy4,101$3.70$15,173.7037,226View SEC Filing Icon  
6/17/2024Andrew CittadineCOOBuy2,400$4.50$10,800.0030,724View SEC Filing Icon  
6/13/2024Andrew CittadineCOOBuy2,400$4.55$10,920.0025,924View SEC Filing Icon  
6/3/2024Andrew CittadineCOOBuy2,400$3.80$9,120.0021,124View SEC Filing Icon  
5/31/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0018,724View SEC Filing Icon  
5/29/2024Andrew CittadineCOOBuy2,400$3.20$7,680.0013,924View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Monopar Therapeutics (NASDAQ:MNPR)

1.83% of Monopar Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Monopar Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025TCG Crossover Management LLC153,000$12.50M0.6%N/A2.290%Search for SEC Filing on Google Icon
11/17/2025Alyeska Investment Group L.P.12,215$1M0.0%N/A0.183%Search for SEC Filing on Google Icon
11/17/2025Vivo Capital LLC90,500$7.39M0.6%N/A1.355%Search for SEC Filing on Google Icon
11/17/2025Susquehanna International Group LLP4,328$0.35M0.0%-48.2%0.065%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC7,334$0.60M0.0%-50.4%0.110%Search for SEC Filing on Google Icon
11/17/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.1,629$0.13M0.0%-26.7%0.024%Search for SEC Filing on Google Icon
11/17/2025Ally Bridge Group NY LLC64,455$5.26M3.2%+86.6%0.965%Search for SEC Filing on Google Icon
11/14/2025Deerfield Management Company L.P.159,765$13.05M0.2%N/A2.589%Search for SEC Filing on Google Icon
11/14/2025ADAR1 Capital Management LLC129,999$10.62M1.0%+28.7%2.107%Search for SEC Filing on Google Icon
11/14/2025Wellington Management Group LLP231,463$18.90M0.0%N/A3.751%Search for SEC Filing on Google Icon
11/13/2025UBS Group AG7,973$0.65M0.0%-63.5%0.129%Search for SEC Filing on Google Icon
11/13/2025BNP Paribas Financial Markets696$57K0.0%+100.6%0.011%Search for SEC Filing on Google Icon
11/13/2025Russell Investments Group Ltd.337$28K0.0%N/A0.005%Search for SEC Filing on Google Icon
11/12/2025Barclays PLC15,082$1.23M0.0%+107.0%0.244%Search for SEC Filing on Google Icon
11/7/2025Vanguard Group Inc.208,218$17.01M0.0%+140.7%3.375%Search for SEC Filing on Google Icon
11/7/2025JPMorgan Chase & Co.1,491$0.12M0.0%-22.4%0.024%Search for SEC Filing on Google Icon
11/6/2025Rhumbline Advisers5,288$0.43M0.0%-9.6%0.086%Search for SEC Filing on Google Icon
11/3/2025AlphaQuest LLC1,935$0.16M0.0%+8.5%0.031%Search for SEC Filing on Google Icon
11/3/2025New York State Common Retirement Fund1,200$98K0.0%-58.6%0.019%Search for SEC Filing on Google Icon
8/15/2025Bank of America Corp DE2,109$75K0.0%-14.9%0.034%Search for SEC Filing on Google Icon
8/14/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.2,222$80K0.0%N/A0.036%Search for SEC Filing on Google Icon
8/13/2025Affinity Asset Advisors LLC67,500$2.42M0.3%+8.9%1.104%Search for SEC Filing on Google Icon
8/13/2025New York State Common Retirement Fund2,900$0.10M0.0%N/A0.047%Search for SEC Filing on Google Icon
8/12/2025Rhumbline Advisers5,850$0.21M0.0%N/A0.096%Search for SEC Filing on Google Icon
8/12/2025JPMorgan Chase & Co.1,921$69K0.0%+1,821.0%0.031%Search for SEC Filing on Google Icon
8/8/2025Police & Firemen s Retirement System of New Jersey964$34K0.0%N/A0.016%Search for SEC Filing on Google Icon
8/8/2025Geode Capital Management LLC96,919$3.47M0.0%+99.7%1.584%Search for SEC Filing on Google Icon
7/31/2025AlphaQuest LLC1,784$64K0.0%+46.8%0.029%Search for SEC Filing on Google Icon
6/27/2025Goldman Sachs Group Inc.18,480$0.67M0.0%N/A0.302%Search for SEC Filing on Google Icon
5/19/2025Jane Street Group LLC10,357$0.38M0.0%N/A0.169%Search for SEC Filing on Google Icon
5/16/2025Goldman Sachs Group Inc.18,480$0.67M0.0%N/A0.302%Search for SEC Filing on Google Icon
5/16/2025ADAR1 Capital Management LLC100,774$3.67M0.7%-22.5%1.648%Search for SEC Filing on Google Icon
5/15/2025OMERS ADMINISTRATION Corp9,000$0.33M0.0%N/A0.147%Search for SEC Filing on Google Icon
5/14/2025Affinity Asset Advisors LLC62,000$2.26M0.2%N/A1.014%Search for SEC Filing on Google Icon
5/14/2025AlphaQuest LLC1,215$44K0.0%N/A0.020%Search for SEC Filing on Google Icon
4/23/2025Gerber LLC5,601$0.20M0.2%N/A0.092%Search for SEC Filing on Google Icon
2/17/2025Point72 Asset Management L.P.167,892$3.69M0.0%N/A2.752%Search for SEC Filing on Google Icon
2/17/2025Janus Henderson Group PLC1,046,899$23.44M0.0%N/A17.162%Search for SEC Filing on Google Icon
2/14/2025RA Capital Management L.P.511,207$11.25M0.1%N/A8.380%Search for SEC Filing on Google Icon
2/14/2025Adage Capital Partners GP L.L.C.599,195$13.18M0.0%N/A9.823%Search for SEC Filing on Google Icon
2/13/2025ADAR1 Capital Management LLC130,037$2.86M0.6%N/A2.132%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC38,596$0.85M0.0%+174.4%0.633%Search for SEC Filing on Google Icon
2/12/2025JPMorgan Chase & Co.2,037$45K0.0%N/A0.033%Search for SEC Filing on Google Icon
10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Monopar Therapeutics logo
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More on Monopar Therapeutics

Today's Range

Now: $79.47
Low: $75.47
High: $79.90

50 Day Range

MA: $85.23
Low: $75.90
High: $102.05

52 Week Range

Now: $79.47
Low: $20.16
High: $105.00

Volume

155,064 shs

Average Volume

168,105 shs

Market Capitalization

$530.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Who are the company insiders with the largest holdings of Monopar Therapeutics?

Monopar Therapeutics' top insider investors include:
  1. Tactic Pharma Llc (Major Shareholder)
  2. Chandler Robinson (CEO)
  3. Andrew Cittadine (COO)
  4. Kim R Tsuchimoto (Director)
  5. Christopher M Starr (Director)
  6. Karthik Radhakrishnan (CFO)
Learn More about top insider investors at Monopar Therapeutics.

Who are the major institutional investors of Monopar Therapeutics?

Monopar Therapeutics' top institutional shareholders include:
  1. Wellington Management Group LLP — 3.75%
  2. Vanguard Group Inc. — 3.37%
  3. Deerfield Management Company L.P. — 2.59%
  4. TCG Crossover Management LLC — 2.29%
  5. ADAR1 Capital Management LLC — 2.11%
  6. Vivo Capital LLC — 1.35%
Learn More about top institutional investors of Monopar Therapeutics stock.

Which major investors are selling Monopar Therapeutics stock?

In the previous quarter, MNPR stock was sold by these institutional investors:
  1. UBS Group AG
  2. Millennium Management LLC
  3. Susquehanna International Group LLP
  4. New York State Common Retirement Fund
  5. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
  6. Rhumbline Advisers
  7. JPMorgan Chase & Co.
In the previous year, company insiders that have sold Monopar Therapeutics company stock include:
  1. Tactic Pharma Llc (Major Shareholder)
  2. Chandler Robinson (CEO)
  3. Andrew Cittadine (COO)
  4. Kim R Tsuchimoto (Director)
Learn More investors selling Monopar Therapeutics stock.

Which major investors are buying Monopar Therapeutics stock?

During the last quarter, MNPR stock was bought by institutional investors including:
  1. Wellington Management Group LLP
  2. Deerfield Management Company L.P.
  3. TCG Crossover Management LLC
  4. Vanguard Group Inc.
  5. Vivo Capital LLC
  6. Ally Bridge Group NY LLC
  7. ADAR1 Capital Management LLC
  8. Alyeska Investment Group L.P.
Within the last year, these company insiders have bought Monopar Therapeutics stock:
  1. Tactic Pharma Llc (Major Shareholder)
  2. Chandler Robinson (CEO)
Learn More investors buying Monopar Therapeutics stock.